围手术期患者恶性高热预防及护理的证据总结

doi:10.3761/j.issn.1672-9234.2023.07.017

摘要/Abstract

摘要：

目的总结国内外围手术期患者恶性高热预防及管理的证据，为临床医护人员提供科学指导和循证依据。方法检索PubMed、UpToDate、中国知网等国内外数据库及相关指南网站中围手术期患者恶性高热预防及管理的相关文献，包括指南、临床决策、证据总结、专家共识、推荐实践、系统评价等，检索时限为建库至2022年8月1日。研究者依据标准进行文献质量评价并提取相关证据。结果最终纳入10篇文献，其中5篇为指南、5篇为专家共识。包括术前管理、抢救处理、对症处理、术后管理、人员要求5个类别，共21条最佳证据。结论本研究总结了围手术期患者恶性高热预防及管理的最佳证据，临床医护人员可结合临床实际选择最佳证据，为提升围手术期患者恶性高热预防及管理水平和质量提供循证依据。

关键词: 恶性高热, 围手术期护理, 证据总结

Abstract:

Objective To collect and summarize the best evidence summary for prevention and management of malignant hyperthermia in perioperative patients at home and abroad，and to provide guidance and evidence for clinical medical staffs. Methods Relevant literatures related to prevention and management of malignant hyperthermia in perioperative patients in domestic and foreign databases were retrieved，including guidelines，clinical decision-making，evidence summaries，expert consensus，recommended practice，and systematic reviews. The retrieval time was from the establishment of the database to August 1，2022. The researchers evaluated the literature quality according to the criteria and extracted relevant evidence. Results A total of 10 articles were included，including 5 guidelines，5 expert consensus. Twenty-one pieces of best evidence was summarized from five aspects：preoperative management，rescue treatment，symptomatic treatment，postoperative management，and personnel requirements. Conclusion This study summarizes the best evidence for prevention and management of malignant hyperthermia in perioperative patients. Clinical medical staffs can select the best evidence in combination with clinical practice to provide evidence-based evidence for improving the level and quality of prevention and management of malignant hyperthermia in perioperative patients.

Key words: Malignant Hyperthermia, Perioperative Nursing, Evidence summary

张亚云, 关丽娜, 金洁, 张恩漫. 围手术期患者恶性高热预防及护理的证据总结[J]. 中华护理教育, 2023, 20(7): 864-869.

ZHANG Yayun, GUAN Lina, JIN Jie, ZHANG Enman. Best evidence summary for prevention and management of malignant hyperthermia in perioperative patients[J]. Chinese Journal of Nursing Education, 2023, 20(7): 864-869.

图/表 3

参考文献 28

[1]	Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020:guideline from the association of anaesthetists[J]. Anaesthesia, 2021, 76(5):655-664. doi: 10.1111/anae.15317 pmid: 33399225
[2]	中国防治恶性高热专家共识工作组. 中国防治恶性高热专家共识(2020版)[J]. 中华麻醉学杂志, 2021, 41(1):20-25.
	China Expert Consensus Working Group on the Prevention and Treatment of Malignant Hyperthermia. Expert consensus on prevention and treatment of malignant hyperthermia in China (2020 edition)[J]. Chin J Anesthesiol, 2021, 41(1):20-25.
[3]	Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis:guidelines from the Euro-pean Malignant Hyperthermia Group[J]. Br J Anaesth, 2010, 105(4):417-420. doi: 10.1093/bja/aeq243 pmid: 20837722
[4]	Association of Surgical Technologists. Guidelines for best practices for treatment of surgical patients experiencing malignant hyperthermia in the operating room[EB/OL].[2022-06-22]. https://www.ast.org/uploadedFiles/Main_Site/Content/About_Us/Gui-deline_Malignant_Hyperthermia.pdf.
[5]	国家卫生健康委办公厅. 2019国家卫生健康委办公厅关于印发麻醉科医疗服务能力建设指南(试行)的通知[EB/OL].(2019-12-18)[2022-08-24]. http://www.gov.cn/xinwen/2019-12/18/content_5462015.htm.
[6]	Julien Marsollier F, Roux-Buisson N, Dalmas AF, et al. Management of malignant hyperthermia in France:current organisation[J]. Anaesth Crit Care Pain Med, 2019, 38(5):535. doi: 10.1016/j.accpm.2019.02.008
[7]	EMHG. About us[EB/OL].[2022-08-24]. https://www.emhg.org/about.
[8]	MHANZ. Healthcare professionals[EB/OL].[2022-08-24]. https://www.mhaus.org/healthcare-professionals/.
[9]	MHANZ. Malignant hyperthermia[EB/OL].[2022-08-24]. https://malignanthyperthermia.org.au/.
[10]	倪叶彬, 陈亚梅, 朱晓萍, 等. 糖尿病患者围手术期血糖管理的证据总结[J]. 中华护理杂志, 2021, 56(7):1079-1085. doi: 10.3761/j.issn.0254-1769.2021.07.021
	Ni YB, Chen YM, Zhu XP, et al. Evidence summary for management of perioperative blood glucose in patients with diabetes mellitus[J]. Chin J Nurs, 2021, 56(7):1079-1085. doi: 10.3761/j.issn.0254-1769.2021.07.021
[11]	周芬, 郝玉芳, 丛雪, 等. 指南研究与评价工具AGREE Ⅱ及各领域分值的补充解释及思考[J]. 护理学报, 2018, 25(18):56-58.
	Zhou F, Hao YF, Cong X, et al. Supplementary explanation and thinking of AGREE Ⅱ,a guide research and evaluation tool,and scores in various fields[J]. J Nurs China, 2018, 25(18):56-58.
[12]	AGREE. AGREE Ⅱ[EB/OL].[2022-06-22]. https://www.agree-trust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf.
[13]	The Joanna Briggs InstituteJBI. Critical appraisal tools[EB/OL].[2022-06-22]. https://jbi.global/critical-appraisal-tools.
[14]	王春青, 胡雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30(11):964-967.
	Wang CQ, Hu Y. JBI evidence pre-classification and evidence rank system(2014 Edition)[J]. J Nurses Train, 2015, 30(11):964-967.
[15]	Glahn KPE, Bendixen D, Girard T, et al. Availability of dan-trolene for the management of malignant hyperthermia crises:European Malignant Hyperthermia Group guidelines[J]. Br J Anaesth, 2020, 125(2):133-140. doi: 10.1016/j.bja.2020.04.089
[16]	Rüffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group[J]. Br J Anaesth, 2021, 126(1):120-130. doi: 10.1016/j.bja.2020.09.029 pmid: 33131754
[17]	Urman RD, Rajan N, Belani K, et al. Malignant hyperthermia susceptible adult patient and ambulatory surgery center:Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American society of anesthesiologists position statement[J]. Anesth Analg, 2019, 129(2):347-349. doi: 10.1213/ANE.0000000000004257
[18]	Safety Committee of Japanese Society of Anesthesiologists. JSA guideline for the management of malignant hyperthermia crisis 2016[J]. J Anesth, 2017, 31(2):307-317. doi: 10.1007/s00540-016-2305-z pmid: 28246924
[19]	MHANZ. Malignant Hyperthermia Resource Kit[EB/OL].[2022-06-22]. https://malignanthyperthermia.org.au/resource-kit/.
[20]	EMHG. Preparation of Anaesthetic Workstations for MH suspected or susceptible patients[EB/OL].(2018-02-27)[2022-06-22]. https://www.emhg.org/recommendations-1/2018/2/27/pre-paration-of-anaesthetic-workstations-for-mh-suspected-or-susceptible-patients.
[21]	Litman RS, Smith VI, Larach MG, et al. Consensus statement of the malignant hyperthermia association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia[J]. Anesth Analg, 2019, 128(4):652-659. doi: 10.1213/ANE.0000000000004039 pmid: 30768455
[22]	Hopkins PM, Rüffert H, Snoeck MM, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility[J]. Br J Anaesth, 2015, 115(4):531-539. doi: 10.1093/bja/aev225 pmid: 26188342
[23]	Susan S, Ther G, Ther M. Hyperthermia:management[EB/OL].(2021-08-04)[2022-07-01]. https://ovidsp.dc2.ovid.com/ovid-a/ovidweb.cgi?&S=CHKLFPCCFCEBBEMCJPNJAHJEBICPAA00& Link+Set=S.sh.48%7c4%7csl_190.
[24]	Nathan N. Perioperative cardiac arrest:focus on malignant hyperthermia(MH)[J]. Anesth Analg, 2018, 126(3):737. doi: 10.1213/ANE.0000000000002831
[25]	Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis:guidelines from the Eu-ropean Malignant Hyperthermia Group[J]. Br J Anaesth, 2010, 105(4):417-420. doi: 10.1093/bja/aeq243 pmid: 20837722
[26]	Rodrigues G, de Andrade PV, dos Santos JM, et al. Impact of a digital manual for guidance on malignant hyperthermia:patient education[J]. Orphanet J Rare Dis, 2022, 17(1):265. doi: 10.1186/s13023-022-02435-1 pmid: 35841058
[27]	Schädler D, Heinrichs W, Mönk S, et al. Simulation training for German anesthesiologists:case scenarios and training re-sults[J]. Anasthesiol Intensivmed Notfallmed Schmerzther, 2008, 43(6):474-477. doi: 10.1055/s-2008-1081395
[28]	Tsioutis C, Birgand G, Bathoorn E, et al. Education and training programmes for infection prevention and control professionals:mapping the current opportunities and local needs in European countries[J]. Antimicrob Resist Infect Control, 2020, 9(1):183. doi: 10.1186/s13756-020-00835-1